Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Oct 13, 2026Closes
Feb 11, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Health
Eligible applicants: Special district governments, Small businesses, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, City or township governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, Native American tribal organizations (other than Federally recognized tribal governments), Native American tribal governments (Federally recognized), Public and State controlled institutions of higher education, For profit organizations other than small businesses, State governments, Private institutions of higher education, Public housing authorities/Indian housing authorities, Others (see text field entitled "Additional Information on Eligibility" for clarification), County governments
Description
The purpose of this notice of funding opportunity (NOFO) is to support research and/or preclinical development of highly efficacious vaccines against malaria - one of the deadliest mosquito-borne diseases - by capitalizing on recent technological innovations, particularly in structure-based immunogen design, improved formulations, and combination vaccines. The goal is to achieve long-lasting, highly effective protection that can save lives, strengthen public health security in the United States, and serve as a model for, or are potentially effective against, other mosquito-borne diseases.